Huseyin Naci
Biographic Data
| ID | 5543199 |
|---|---|
| NAME | Huseyin Naci |
| GIVEN NAMES | Huseyin |
| FAMILY NAME | Naci |
| SIGNATURE | NACI H |
| AFFILIATIONS | London School of Economics and Political Science |
| ORCID | 0000-0002-7192-5751 |
| VERIFIED | Yes |
| TOTAL WORKS | 7 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 7 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2014 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Global norms, local institutions
Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015–2021
INTRODUCTION: We examined overall survival (OS) benefits for targeted cancer drugs recommended for List of Essential Medicines (EMLs) since 2015. We assessed consistency of decisions in 2019 and 2021 with more specific criteria: OS benefit >4 months and high scores on European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS). METHODS: We identified applications for cancer drug in WHO EMLs from 2015 to 2021. We extracte…
Characteristics of Prior Authorization Policies for New Drugs in Medicare Part D
This cross-sectional study examines the characteristics of prior authorization policies for new drugs in Medicare Part D to understand whether they are consistent with US Food and Drug Administration indications
Ultraexpensive gene therapies, industry interests and the right to health
Negotiating Drug Prices in the US—Lessons From Europe
This Viewpoint describes European drug price negotiation practices and compares them with practices in the US
The Cyprus Women’s Health Research (Cohere) initiative
These are the first population normative values published from a large representative sample of women between 18 and 55 years from the Eastern Mediterranean region. We found better physical health in younger women and better mental health in older women. Turkish Cypriot women and non-migrant women had better mental health, and HRQOL was highest in those in paid employment and those with a higher educational achievement
Persistent Medication Affordability Problems Among Disabled Medicare Beneficiaries After Part D, 2006–2011
BACKGROUND: Disabled Americans who qualify for Medicare coverage typically have multiple chronic conditions, are highly dependent on effective drug therapy, and have limited financial resources, putting them at risk for cost-related medication nonadherence (CRN). Since 2006, the Part D benefit has helped Medicare beneficiaries afford medications. OBJECTIVE: To investigate recent national trends in medication affordability among this vulnerable po…
No prominent works on this page.
Persistent Medication Affordability Problems Among Disabled Medicare Beneficiaries After Part D, 2006–2011
BACKGROUND: Disabled Americans who qualify for Medicare coverage typically have multiple chronic conditions, are highly dependent on effective drug therapy, and have limited financial resources, putting them at risk for cost-related medication nonadherence (CRN). Since 2006, the Part D benefit has helped Medicare beneficiaries afford medications. OBJECTIVE: To investigate recent national trends in medication affordability among this vulnerable po…
Ultraexpensive gene therapies, industry interests and the right to health
Negotiating Drug Prices in the US—Lessons From Europe
This Viewpoint describes European drug price negotiation practices and compares them with practices in the US
The Cyprus Women’s Health Research (Cohere) initiative
These are the first population normative values published from a large representative sample of women between 18 and 55 years from the Eastern Mediterranean region. We found better physical health in younger women and better mental health in older women. Turkish Cypriot women and non-migrant women had better mental health, and HRQOL was highest in those in paid employment and those with a higher educational achievement
Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015–2021
INTRODUCTION: We examined overall survival (OS) benefits for targeted cancer drugs recommended for List of Essential Medicines (EMLs) since 2015. We assessed consistency of decisions in 2019 and 2021 with more specific criteria: OS benefit >4 months and high scores on European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS). METHODS: We identified applications for cancer drug in WHO EMLs from 2015 to 2021. We extracte…
Characteristics of Prior Authorization Policies for New Drugs in Medicare Part D
This cross-sectional study examines the characteristics of prior authorization policies for new drugs in Medicare Part D to understand whether they are consistent with US Food and Drug Administration indications
Global norms, local institutions
Medicine (6 works) · Health Systems, Economic Evaluations, Quality of Life (4 works) · Pharmaceutical Economics and Policy (4 works) · Business (3 works) · Drug (3 works) · Nursing (3 works) · Pharmacology (3 works) · Political science (3 works) · Demography (2 works) · Economic and Financial Impacts of Cancer (2 works)